Posted in | News

New Joint Venture Aim to Expand Bromine Industry in China

Albemarle Corporation and Weifang Sinobrom Import and Export Company, Ltd. (Sinobrom) have reached an agreement in principle to form a new joint venture that will combine the existing business of Sinobrom, a leading marketer of bromine derivatives in China, with Albemarle's global bromine expertise in the specialty chemical industry.

The new joint venture, Sinobrom Albemarle Bromine Chemicals (Shandong) Company Ltd., will be 75-percent owned by Albemarle's subsidiary, Albemarle Holdings Limited, with the remaining 25 percent to be held by Sinobrom. The launch of the joint venture is subject to final approval by the Chinese authorities, which is expected within 60 to 90 days.

Concurrently with its launch, the joint venture will enter into an exclusive agreement with Shandong Weitai Fine Chemical Company, Ltd. (Weitai), a producer of bromine derivatives located in Xinhe Town, Pingdu, China. Under this agreement, all Weitai products will be exclusively marketed by the joint venture.

"Sinobrom is a leader in the Chinese bromine derivatives industry, with strong market positions and impressive global reach. The combination of Sinobrom's strengths and Albemarle's leadership position in the bromine industry will create a new growth platform for Albemarle in Shandong province, the heart of the Chinese bromine and derivatives market," said Matt Juneau, Albemarle's performance chemicals division vice president.

"We are excited about the opportunity to partner with Albemarle," said Li Chun, general manager of Sinobrom. "Albemarle brings commercial, technical, and environmental leadership in the bromine industry. We expect to accelerate our growth both in China and around the world through this new partnership."

Posted May 16th,2008

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.